ATE247476T1 - Verfahren zur behandlung von interstitieller blasenentzündung mit hyaluronsäure - Google Patents

Verfahren zur behandlung von interstitieller blasenentzündung mit hyaluronsäure

Info

Publication number
ATE247476T1
ATE247476T1 AT96901681T AT96901681T ATE247476T1 AT E247476 T1 ATE247476 T1 AT E247476T1 AT 96901681 T AT96901681 T AT 96901681T AT 96901681 T AT96901681 T AT 96901681T AT E247476 T1 ATE247476 T1 AT E247476T1
Authority
AT
Austria
Prior art keywords
hyaluronic acid
blidder
inflammation
treating interstitial
interstitial cystitis
Prior art date
Application number
AT96901681T
Other languages
English (en)
Inventor
Alvaro Morales
Stanley J Alkemade
Original Assignee
Bioniche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/388,038 external-priority patent/US5591724A/en
Application filed by Bioniche Inc filed Critical Bioniche Inc
Application granted granted Critical
Publication of ATE247476T1 publication Critical patent/ATE247476T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96901681T 1995-02-14 1996-02-14 Verfahren zur behandlung von interstitieller blasenentzündung mit hyaluronsäure ATE247476T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/388,038 US5591724A (en) 1995-02-14 1995-02-14 Method for treating the urinary bladder and associated structures using hyaluronic acid
US59101596A 1996-02-08 1996-02-08
PCT/CA1996/000094 WO1996025168A1 (en) 1995-02-14 1996-02-14 Use of hyaluronic acid for the treatment of interstitial cystitis

Publications (1)

Publication Number Publication Date
ATE247476T1 true ATE247476T1 (de) 2003-09-15

Family

ID=27012116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96901681T ATE247476T1 (de) 1995-02-14 1996-02-14 Verfahren zur behandlung von interstitieller blasenentzündung mit hyaluronsäure

Country Status (20)

Country Link
US (1) US5888986A (de)
EP (1) EP0813417B1 (de)
JP (1) JP4354528B2 (de)
KR (1) KR100268660B1 (de)
CN (1) CN1181016A (de)
AT (1) ATE247476T1 (de)
AU (1) AU705289B2 (de)
BR (1) BR9607601A (de)
CA (1) CA2203621C (de)
CZ (1) CZ288218B6 (de)
DE (1) DE69629553T2 (de)
DK (1) DK0813417T3 (de)
ES (1) ES2205013T3 (de)
HU (1) HUP9800467A3 (de)
IN (1) IN181358B (de)
NO (1) NO315842B1 (de)
NZ (1) NZ300903A (de)
PT (1) PT813417E (de)
TR (1) TR199700782T1 (de)
WO (1) WO1996025168A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0952855B1 (de) * 1991-07-03 2005-07-27 Meditech Research Limited Verwendung von hyaluronan in gentherapie
US6548487B2 (en) 1996-12-27 2003-04-15 Seikagaku Corporation Agent for treatment of bladder troubles
CA2247389C (en) * 1996-12-27 2009-11-24 Seikagaku Corporation Agent for treatment of bladder troubles
CA2347110C (en) 1998-10-22 2008-08-26 Bioniche Life Sciences Inc. A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
HUP0300627A3 (en) * 1999-12-13 2005-11-28 Bioniche Life Sciences Inc Bel Therapeutically useful synthetic oligonucleotides
NZ520312A (en) * 1999-12-28 2003-08-29 Bioniche Life Sciences Inc Hyaluronic acid in the treatment of cancer
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
ES2748058T3 (es) * 2005-01-14 2020-03-12 Urigen Inc Kits y composiciones para tratar trastornos del tracto urinario inferior
DE102006060953A1 (de) * 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
TWI383796B (zh) 2009-08-14 2013-02-01 Holy Stone Healthcare Co Ltd Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer
TWI516269B (zh) 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
HUP0900717A3 (en) * 2009-11-18 2012-02-28 Richter Gedeon Nyrt Pharmaceutical composition for urological use containing zinc hyaluronate
US8575130B2 (en) * 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US20110166098A1 (en) * 2010-01-04 2011-07-07 Wu Tsung-Chung Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
ES2665254T3 (es) * 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
ITMI20111732A1 (it) * 2011-09-27 2013-03-28 Bsdpharma Srl Formulazioni farmaceutiche per la riduzione della sensibilizzazione crociata tra colon-retto ed il distretto urogenitale con mezzi non-farmacologici.
RU2519010C1 (ru) * 2013-03-20 2014-06-10 Общество с ограниченной ответственностью "КОЛЕТЕКС" Композиция для лечения цистита
WO2015018461A1 (fr) 2013-08-09 2015-02-12 Genbiotech Compositions therapeutiques comprenant d'acide hyaluronique
CN103655601B (zh) * 2013-12-31 2019-10-25 上海建华精细生物制品有限公司 一种用于膀胱灌洗的组合物
CN103861091B (zh) * 2014-03-20 2016-04-27 辽宁亿灵科创生物医药科技有限公司 治疗膀胱炎的药物组合物
US20170189564A9 (en) * 2014-04-03 2017-07-06 Lipella Pharmaceuticals, Inc. Systems and methods of detecting interstitial cystitis
RU2557949C1 (ru) * 2014-08-14 2015-07-27 Общество с ограниченной ответственностью "КОЛЕТЕКС" Способ лечения лучевого и интерстициального цистита
GB201616838D0 (en) * 2016-10-04 2016-11-16 Nat Univ Ireland Hyaluronan compositions, and uses thereof in treatment of interstitial cystitis
EP3400951B1 (de) * 2017-05-12 2019-12-11 Farco-Pharma GmbH Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (4,5 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US4302577A (en) * 1979-10-05 1981-11-24 Biomed Research Inc. Process for preparing CSA or CSC
US5180715A (en) * 1980-11-17 1993-01-19 The Regents Of The University Of California Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
DE3118588C2 (de) * 1981-05-11 1983-07-07 Luitpold-Werk, Chemisch-Pharmazeutische Fabrik, 8000 München Verfahren zur Herstellung eines injizierbaren hochreinen Chondroitinpolysulfates, hiernach erhältliches Produkt und pharmazeutische Zusammensetzung
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4966890A (en) * 1986-04-04 1990-10-30 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US5037810A (en) * 1987-03-17 1991-08-06 Saliba Jr Michael J Medical application for heparin and related molecules
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
EP0572932B1 (de) * 1992-06-02 2000-09-13 C.R. Bard, Inc. Verfahren und Implantatvorrichtung für Langzeitwirkstoffabgabe
CA2158638C (en) * 1993-03-19 1999-11-30 Bengt Agerup A composition and a method for tissue augmentation

Also Published As

Publication number Publication date
TR199700782T1 (xx) 1998-03-21
CA2203621A1 (en) 1996-08-22
DE69629553T2 (de) 2004-06-17
KR19980702251A (ko) 1998-07-15
DE69629553D1 (de) 2003-09-25
BR9607601A (pt) 1999-09-14
US5888986A (en) 1999-03-30
ES2205013T3 (es) 2004-05-01
CA2203621C (en) 1998-04-28
NZ300903A (en) 1999-07-29
MX9706182A (es) 1998-07-31
CN1181016A (zh) 1998-05-06
NO973732L (no) 1997-10-10
AU4617996A (en) 1996-09-04
JP4354528B2 (ja) 2009-10-28
AU705289B2 (en) 1999-05-20
EP0813417B1 (de) 2003-08-20
CZ257497A3 (cs) 1998-01-14
EP0813417A1 (de) 1997-12-29
PT813417E (pt) 2003-12-31
WO1996025168A1 (en) 1996-08-22
NO973732D0 (no) 1997-08-13
HUP9800467A3 (en) 1999-01-28
HUP9800467A2 (hu) 1998-06-29
NO315842B1 (no) 2003-11-03
JPH10513476A (ja) 1998-12-22
CZ288218B6 (en) 2001-05-16
KR100268660B1 (ko) 2000-10-16
IN181358B (de) 1998-05-30
DK0813417T3 (da) 2003-11-03

Similar Documents

Publication Publication Date Title
ATE247476T1 (de) Verfahren zur behandlung von interstitieller blasenentzündung mit hyaluronsäure
PL338705A1 (en) Application of gaba analogues in preventing and treating gastrointestinal diseases
ZA988278B (en) Ionic polymers as toxin-binding agents
IL123500A0 (en) Composite biomaterials for preventing post-surgical adhesions of tissues
GB9807639D0 (en) Anti-inflammatory agents
WO2002056895A3 (en) Ionene polymers and their use in treating mucositis
ATE193443T1 (de) Verwendung eines imidazols zur herstellung eines medikamentes zur behandlung der arteriosklerose
ATE231722T1 (de) Verfahren zur vermeidung von skelettproblemen beim geflügel
ATE261307T1 (de) Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen
BR8907770A (pt) Solucao para tratamento de metal,solucao aquosa e processo para tratar uma superficie de metal
DE69027220D1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
DE69721747D1 (de) Methode zur behandlung oder verhütung von interstitieller blasenentzundung
ATE264674T1 (de) Verwendung von hyaluronsäure zur behandlung der bestrahlungs-blasenentzündung
Hølund et al. The value of hyaluronidase treatment of different tissues before demonstration of fibronectin by the indirect immunoperoxidase technique
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
FI962549A (fi) Metallinen siirrännäinen ja menetelmä metallisen siirrännäisen käsittelemiseksi
DE69835210D1 (de) Verwendung von hyaluronidase zur herstellung eines arzneimittels zur behandlung von entzündungen
DE69428120D1 (de) Lokal anwendbares präparat zur reepithelisierung bei andauernden epitheldefekten
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
RU97115451A (ru) Способ лечения интерстициального цистита
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ATE291431T1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.
RU96118184A (ru) Способ лечения рефлекторных синдромов при остеохондрозе
RU94007838A (ru) Способ лечения геморрагической лихорадки с почечным синдромом

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0813417

Country of ref document: EP

EEIH Change in the person of patent owner